Makena Is Just the Latest in Accelerated Approval Mayhem

(MedPage Today) -- Last week, after a 3-day hearing, an FDA advisory panel voted 14-1 that 17α-hydroxyprogesterone caproate (17-OHPC; Makena) should be withdrawn from the market. Back in 2011, based on preliminary evidence that the synthetic...